Introduction
Neuroblastoma is the most common extracranial solid tumor in children and is responsible for 15% of all cancer-related deaths within this population. Multidisciplinary therapeutic approaches including chemotherapy, bone marrow transplantation, radical tumor resections and radiation therapy have affected the outcomes in low-risk neuroblastoma. However, o20% of patients with high-risk neuroblastoma live past 5 years (Brodeur, 2003) . These high-risk patients are the most difficult to treat because of the highly resistant nature of these tumors. Many clinical trials are underway to target these therapy resistance pathways using small molecule inhibitors in hopes of increasing the efficacy of current treatment modalities.
The tumor suppressor p53 is a nuclear transcription factor that has a central role in the pathogenesis of human cancers (Levine, 1997; Hupp et al., 2000; Vogelstein et al., 2000) . The p53 protein is normally expressed at low levels in a latent form in the cytoplasm. Many stress signals and oncogenic changes activate p53 protein and lead to cell cycle arrest or apoptotic cell death. The regulation of p53 tumor suppressor activity is complex and includes posttranslational events such as phosphorylation and acetylation. Phosphorylation at several serine and threonine residues in p53 has been shown to occur after cells are exposed to DNAdamaging agents and is critical for p53 to function as an effective tumor suppressor (Kruse and Gu, 2009) . Aberrant regulation of the p53 tumor suppressor pathway has been suggested as an important mechanism of chemoresistance in neuroblastoma (Tweddle et al., 2003) .
Available evidence suggests that neuroblastoma maintains functional p53; however, the downstream apoptotic mechanisms are suppressed in the majority of primary and relapsed cases (Moll et al., 1995; Goldman et al., 1996; Chen et al., 2007) . More than 50% of all human cancers have p53 gene mutations or deletions (Vousden and Lu, 2002) . The p53 protein is mostly wild type (WT) in neuroblastoma, suggesting that inhibition of p53 tumor suppressor function contributes to chemoresistance, tumor metastasis and poor patient survival (Moll et al, 1995; Tweddle et al., 2001) . Thus, the strategy of restoring p53 function represents an attractive therapeutic approach to this cancer (Tweddle et al., 2003) .
Dual-specificity phosphatases (DUSPs) are a subset of protein tyrosine phosphatases, many of which dephosphorylate serine, threonine, and tyrosine residues on mitogen-activated protein kinases, and hence are also referred to as mitogen-activated protein kinase phosphatases. This group of phosphatases has been shown to have an important role in the regulation of intracellular signaling cascades governing cell growth, differentiation and apoptosis (Jeffrey et al., 2007; Patterson et al., 2009) . In some types of cancer cells, the expression level of a DUSP with oncogenic potential is elevated. For example, overexpression of the Cdc25 phosphatase in many tumors is associated with a poor prognosis (Pestell et al., 2000) . In other cancers, a DUSP with tumor suppression potential is inactivated. For example, the DUSP6/mitogen-activated protein kinase phophatase-3 protein has been suggested to be a strong candidate tumor suppressor gene at 12q22 locus in pancreatic cancer (Furukawa et al., 2003) . In our previous report, we cloned and identified DUSP26, also known as mitogen-activated protein kinase phophatase-8, as a p38 phosphatase (Vasudevan et al., 2005) . Moreover, recent studies suggest DUSP26 could promote cell survival of anaplastic thyroid cancer cells by inhibiting p38 kinase phosphorylation (Yu et al., 2007) .
In this study, we examine the role of DUSP26 in the resistance of neuroblastoma cells to doxorubicininduced apoptosis. We provide experimental evidence that DUSP26 inhibits p53 tumor suppressor function by dephosphorylating p53 at Ser20 and Ser37 and contributes to the resistance of neuroblastoma cells to doxorubicin-induced apoptosis.
Results

DUSP26 is overexpressed in majority of human neuroblastoma cell lines and primary tissue specimens
To test the prevalence of DUSP26 expression in neuroblastoma, we first measured the protein and mRNA levels of DUSP26 in seven cultured neuroblastoma cell lines. As shown in Figure 1a , five of the seven neuroblastoma cell lines have high levels of DUSP26 mRNA expression, ranging from 25.8 to 107.5-fold higher than the low expressing SK-N-AS and SK-N-SH cell lines. In addition, these five neuroblastoma cell lines have high DUSP26 protein expression (Figure 1b) .
Using a rabbit-polyclonal antibody against DUSP26, we stained paraffin-embedded tissue samples for DUSP26 expression. A total of 17 samples were stained and read in a blinded manner by an attending pediatric pathologist. Figure 1c shows the specificity of DUSP26 staining in the neuroblastoma cells; whereas, the adjacent normal adrenal tissue shows minimal to no staining. We analyzed DUSP26 expression with an immunohistochemistry score determined by adding the % cells stained score (scale of 1-4) and staining intensity score (scale 1-3) for a total score scale of 1-7. The high-risk neuroblastoma samples (categorized according to the Children's Oncology Group risk stratification system) showed the highest levels of DUSP26 expression with a mean score of 5.14. This was statistically significant compared with the low-risk group when analyzed with Student's t-test (Supplementary Table 1 ).
As DUSP26 was previously shown to be amplified at the DNA level in anaplastic thyroid cancer (Yu et al., 2007) , we performed fluorescence in situ hybridization analysis of DUSP26 with six neuroblastoma cell lines and found that DUSP26 is not amplified in these neuroblastoma cell lines (data not shown).
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β-actin Figure 2c ). To confirm this result, we examined the effect of DUSP26 knockdown on doxorubicin-induced PARP cleavage. In this assay, we found that both sh-DUSP26 cell lines show more doxorubicin-induced PARP cleavage compared with sh-Control cells (Figure 2d ). To further validate our results, we also overexpressed DUSP26-WT and -C152S (CS) phosphatase-deficient mutant in p53 WT SK-N-SH cells with a low baseline expression of DUSP26. In this assay, we found that overexpression of DUSP26-WT promoted the resistance of the cells to doxorubicin-induced cellular toxicity and PARP cleavage compared with the vector control and DUSP26-CS mutant (Figures 2e-g ).
DUSP26 modulates p53 phosphorylation and function in neuroblastoma cells
To determine the mechanism of DUSP26 function in chemoresistance of neuroblatoma cells, we tested the effects of DUSP26 suppression and overexpression on After 24 h of growth, all of the cell lines were treated with the indicated mM concentration of doxorubicin for 24 h. Cell viability was determined with the CCK-8 cell viability assay relative to the 0 mM group. All experiments were performed in triplicate and statistical significance was determined by Student's t-test comparing DUSP26-WT with the vector control group where *Po0.05 and **Po0.001. (g) The SK-N-SH pBabe-vector control, DUSP26-WT and DUSP26-CS cells were seeded into 6-cm dishes for two days. The cells were either left untreated or stimulated with 3 mM doxorubicin for 4, 6 or 8 h. After that, cells were harvested and subjected to immunoblotting analysis with anti-PARP antibodies.
DUSP26 is a novel p53 phosphatase X Shang et al doxorubicin-induced p53 phosphorylation and activation in neuroblastoma cells. In this assay, we used a group of anti-phospho-p53 antibodies to screen the possible phospho-p53 residues that are modulated by DUSP26 in neuroblastoma cells. Interestingly, we found that knockdown of DUSP26 expression significantly enhanced doxorubicin-induced p53 phosphorylation at Ser20 and Ser37 residues in IMR-32 neuroblastoma cell line. In addition, overexpression of DUSP26-WT inhibited p53 phosphorylation at Ser20 and Ser37 residues compared with vector control and DUSP26-CS mutant in the transduced SK-N-SH cells (Figures 3a  and c) . Consistent with this result, doxorubicin induced a higher level of p21 expression in IMR-32 cells with DUSP26 knockdown whereas overexpression of DUSP26-WT but not -CS mutant inhibited doxorubicin-induced p21 expression in SK-N-SH cells ( Figures  3b-d) . Furthermore, we also found that doxorubicin induced a higher level of p53 target genes such as Bax, p53AIP1 and Puma in DUSP26 knockdown IMR-32 cells whereas overexpression of DUSP26-WT but not -CS mutant inhibited the expression of Bax, p53AIP1 and Puma in SK-N-SH cells (Supplementary Figure 1) . We also found that knockdown of DUSP26 expression enhanced doxorubicin-induced p53 phosphorylation, p53 target gene expression and apoptosis in SH-SY5Y-another neuroblastoma cell line with higher DUSP26 expression (Supplementary Figure 2) . In addition, we found that DUSP26 expression negatively modulated etoposide (VP-16)-induced p53 phosphorylation, p53 target gene expression and apoptosis in a similar manner to the effect observed with doxorubicin ( Supplementary Figures 3a and b) .
DUSP26 modulates p53 function by binding to and dephosphorylating p53 at Ser20 and Ser37
Having established a connection between DUSP26 phosphatase activity and p53 phosphorylation and downstream function, we further examined the functional interactions between DUSP26 and p53. The p53-dependent MDM2-luciferase reporter plasmid was first transfected with or without the p53 expression plasmid into Saos-2 cells stably transduced with empty vector, DUSP26-WT or -CS mutant. Then cells were treated with or without doxorubicin. In this assay, we found that DUSP26-WT strongly inhibits p53-dependent MDM2-luciferase reporter activity compared with vector control and DUSP26-CS mutant (Figure 4a) . A similar result was obtained when the p53-dependent Bax-luciferase reporter plasmid was used in this assay ( Figure 4b ). To determine whether DUSP26 physically binds to p53, we co-transfected the green fluorescent protein-p53 expression plasmid with vector control or FLAG-DUSP26 into HEK293T cells. The FLAG-DUSP26 proteins were immunoprecipitated from the cell lysates with anti-FLAG antibodies and immunoblotted with antibodies specific for p53 (DO-1). As shown in Figure 4c , we found that FLAG-DUSP26 pulls down green fluorescent protein-p53. Consistently, we found Sh-DUSP26-2 Sh-DUSP26-1
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Figure 3 DUSP26 inhibits doxorubicin-induced p53 phosphorylation at Ser-20 and Ser-37 residues and downstream p53 activity. Sh-Control, sh-DUSP26-1 and sh-DUSP26-2 IMR-32 cells were seeded into 6-cm dishes for 2 days and then were either left untreated or treated with 3 mM of DOX for 1, 2, 4 or 8 h. Then cells were harvested and subjected to immunoblotting analysis with an array of (a) anti-phospho-p53 and (b) anti-p21 antibodies. (c) Vector control, DUSP26-WT and -CS mutant SK-N-SH cell lines were seeded into 6-cm dishes for 2 days and then were either left untreated or treated with 3 mM of DOX for 4, 6 or 8 h. Cells were then harvested and subjected to immunoblotting analysis with anti-p53-pSer20, -pSer37, p53 (DO-1) and anti-p21 antibodies. Figure 4a) . Using an in vitro assay with recombinant protein, we found that recombinant glutathione S-transferase (GST)-DUSP26-WT binds to both endogenous and overexpressed p53 from HEK293T cell lysates (Figure 4d ). We also found that the GST-DUSP26-CS mutant binds overexpressed p53 in HEK293T cells suggesting that this binding occur independent of the phosphatase activity ( Supplementary  Figure 4b) . Furthermore, recombinant GST-DUSP26-WT binds to recombinant His-p53 in vitro, suggesting that that these two proteins directly bind without any intermediary proteins (Figure 4e) .
The anti-DUSP26 antibodies were tested for DUSP26 immunoprecipitation using the FLAG-DUSP26 expres- 
DUSP26 is a novel p53 phosphatase X Shang et al sion plasmid in HEK293T cells. We found effective immunoprecipitation of FLAG-DUSP26 as confirmed by immunoblotting with anti-FLAG antibodies (Supplementary Figure 5a ). To further confirm the interaction between DUSP26 and p53 in neuroblastoma cells, neuroblastoma cells were first treated with doxorubicin to induce p53 expression, and then endogenous DUSP26 was immunoprecipitated from IMR-32 cell lysate with anti-DUSP26 antibodies and immunoblotted for p53. As shown in Figure 4f , endogenous DUSP26 coimmunoprecipitates with endogenous p53. Effective p53 immunoprecipitation also found in an additional neuroblastoma cell line SH-SY5Y with a high endogenous DUSP26 expression (Supplmentary Figure 5b) . To further confirm the role of DUSP26 as a p53 phosphatase targeting on p53 Ser20 and Ser37 residues, we performed an in vitro phosphatase assay to address whether DUSP26 directly dephosphorylates p53 at these two sites. In this assay, p53 Ser15, Ser20 and Ser37 phosphopeptides were co-incubated with recombinant GST-DUSP26-WT and -CS mutant proteins in an in vitro phosphatase reaction. DUSP26 WT showed a higher level phosphatase activity toward p53 phosphoSer20 and phospho-Ser37 compared with phosphoSer15 (Figure 4g ). These results strongly suggest that DUSP26 physically interacts with p53 and functionally inhibits p53 function by modulating p53 phosphorylation at Ser20 and Ser37 residues in neuroblastoma cells.
Discussion
Neuroblastoma is a p53 WT tumor for which relapse with chemoresistant disease is the primay cause of death (Brodeur, 2003) . The mechanism for this chemoresistance in the presence of intact apoptotic machinery remains unclear. In this study, we examine the role of DUSP26 in promoting neuroblastoma chemoresistance. As has been shown with other important DUSPs, we present evidence that DUSP26 is overexpressed in neuroblastoma cell lines and in high-risk neuroblastoma tissue samples. The highrisk tissue samples represent patients with high-risk features such as age 41 year of age, MYCN amplification, poorly differentiated histopathologic characteristics and poor prognosis (London et al., 2005) .
Our studies show that DUSP26 overexpression may be one of the mechanisms by which neuroblastoma develops chemoresistance. We found that overexpression of DUSP26 in a low DUSP26 expressing cell line increased cell viability in the setting of doxorubicin treatment by both cell viability assay and PARP cleavage. With DUSP26 inhibition with short hairpin RNA, the cells became more chemosensitive to doxorubicin treatment showing that p53 is essential for chemotherapy-related cell death in neuroblastoma. Doxorubicin-induced genotoxic stress is an accepted model of p53 transactivation and has been a mainstay of therapy for neuroblastoma for many years (Lowe et al., 1994; Matthay et al., 1998) .
In neuroblastoma, the p53 protein is most commonly in the WT form and is functional. p53 has an essential role in tumor suppression and in the cellular response to stress (Toledo and Wahl, 2006) . Phosphorylation of p53 protein is involved in the regulation of p53 protein stability and biochemical activities. Many serine residues within the N-and C-terminal regions of p53 are phosphorylated in response to stress conditions such as hypoxia and DNA damage (Kruse and Gu, 2009 ). Both Ser20 and Ser37 phosphorylation on the p53 protein has been shown to have an important role in p53 stability and downstream apoptotic function (Chehnab et al., 1999; Unger et al., 1999; Li et al., 2006; Amano et al., 2009) .
Previously, human Cdc14 phosphatase has been reported to interact with and dephosphorylate p53 at Ser-315 while PPM1D dephosphorylates p53 at Ser15 without binding (Li et al., 2000; Lu et al., 2005) . The results from our in vitro phosphatase assays suggest that p53 Ser20 and Ser37 are specifically targeted by DUSP26 compared with Ser15. In addition, our DUSP26 knockdown and overexpression data further suggest that p53 Ser20 and Ser37 are targeted in vivo by DUSP26. These data indicate that phosphorylation of Ser20 and Ser37 facilitate p53 tumor suppressor function in neuroblastoma. Overexpression of DUSP26 in neuroblastoma results in physical binding and dephosphorylation of p53 in vivo which downregulates p53 tumor suppressor activity in neuroblastoma cells in response to doxorubicin. Interestingly, we found that doxorubincin and VP-16-induced p21 expression was partially inhibited by DUSP26-CS mutant (Figure 3c,  Supplementary Figure 3b) . One explanation is that DUSP26-CS mutant may still have residual phosphatase activity. However, we can not exclude the possibility DUSP26 is a novel p53 phosphatase X Shang et al that binding of DUSP26-CS mutant to p53 causes some level of inhibition. It is also possible that the physical interaction of DUSP26-p53 and the enzymatic activity of DUSP26 both have inhibitory effects on p53 phosphorylation.
Our data, in conjunction with previous studies, suggest a model in which genotoxic stress/DNA damage causes p53 induction and phosphorylation in neuroblastoma. DUSP26 binds to and dephosphorylates p53 at Ser 20 and Ser37 to inhibit p53 tumor suppressor function in neuroblastoma cells ( Figure 5 ). We suggest that overexpression of DUSP26 has an important role in the capacity of neuroblastoma cells to overcome the mechanisms that promote apoptosis and inhibit tumor progression.
Thus, overexpression of DUSP26 may be one of the mechanisms in neuroblastoma to escape doxorubincininduced cell death and gain chemoresistence. Therefore, therapies designed to interfere with the DUSP26-p53 functional interaction would increase chemosensitivity by reactivating cellular apoptosis pathways to promote tumor cell death and better response to therapy.
Materials and methods
Patients and tumor tissue collection
The neuroblastoma patients participating in this study were recruited from the Texas Children's Cancer Center at Texas Children's Hospital in Houston, TX, USA from 1995 through 2006. All of the procedures were approved by an institutional review board. Fresh tumor tissues were collected from patients with pathologically and clinically confirmed neuroblastoma. A portion of tumor specimens were kept in À80 1C and sectioned for total RNA and protein extraction. Children's Oncology Group risk group and INSS stage assignments were conducted by reference to the medical record.
Cell culture and compound treatment Human neuroblastoma tumor cell lines (IMR-32, SK-N-SH, SH-SY5Y, SK-N-AS, LAN-1) and HEK293T cells, were obtained from the American Type Culture Collection, (Manassas, VA, USA), and the neuroblastoma cell lines SMS-KCN and PCL-5134 were kindly provided by Dr A Davidoff at the St Jude's Children's Hospital, Memphis, TN, USA. Briefly, cell lines were maintained in minimum essential medium (IMR-32, SK-N-SH, SH-SY5Y, Lan-1), and in Dulbecco's modified Eagle's medium (SK-N-AS, HEK293T). All of media were supplemented with 10% heatinactivated fetal calf serum, 2 mM glutamine, 100 units/ml penicillin and 100 mg/ml streptomycin (all from Invitrogen, Gaithersburg, MD, USA). Doxorubicin and VP-16 (SigmaAldrich) were diluted in Hanks' balanced salt solution buffer and dimethylsulphoxide, respectively, and added to the cell culture medium at a final concentration of 0.05-3 mM.
Quantitative reverse transcription-PCR Total RNA was extracted from tumor cell lines using TRIZOL(R) reagent (Invitrogen, Carlsbad, CA, USA), and the purity of RNA was determined by measuring the absorbance at 260/280 nm (A260/A280) in a spectrophotometer. The following primer pairs were used: DUSP26 mRNA (forward, 5 0 -AACCTGTCTTGGGCAGAAAC-3 0 ; reverse
0 -GACGACCTCAACGCACAGTA-3 0 ; reverse, 5 0 -GG AGTCCCATGATGAGATTGT-3 0 ) and glyceraldehyde 3-phosphate dehydrogenase mRNA (forward, 5 0 -CCACATCGCTCA GACACCAT-3 0 ; reverse 5 0 -GGCAACAATATCCACTTTACC AGAGT-3 0 ). Glyceraldehyde 3-phosphate dehydrogenase was used as internal control.
Antibodies
Antibodies specific for anti-p53-pSer9, anti-p53-pSer15, anti-p53-pSer20, anti-p53-pSer37, anti-p53-pSer315, anti-p53-pSer392, anti-Puma, horseradish peroxidase-linked anti-rabbit immunoglobulin secondary antibodies and horseradish peroxidase-linked anti-mouse immunoglobulin were from Cell Signaling Technology. Anti-b-actin, anti-FLAG-M2 were from Sigma-Aldrich. Anti-DUSP26 was from MBL International Corporation. , anti-p53 (DO-1), and horseradish peroxidase-linked anti-goat immunoglobulin secondary antibodies were from Santa Cruz Biotechnology.
Immunohistochemical staining
Immunohistochemical was performed to detect DUSP26 protein expression on sections of paraffin-embedded neuroblastoma tumor tissue. Immunohistochemical staining was performed using Two-Step Histostaining Reagent (Zymed Laboratories Inc., South San Francisco, CA, USA) according to the manufacturer's instructions. The anti-DUSP26 antibody (1:50) was used as primary antibody. Diaminobenzidine tetrahydrochloride was then used as a chromogen, followed by counterstaining with hematoxylin solution.
Immunoblotting and immunoprecipitation
Cells were harvested in ice-cold phosphate-buffered saline (pH 7.4) and spun down. The pellets were dissolved in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% IGEPAL, 0.25% Na-deoxycholate, 1 mM DUSP26 is a novel p53 phosphatase X Shang et al phenylmethyl-sulfonyl fluoride, 1 mM dithiothreitol, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM benzamidine, 20 mM disodium p-nitrophenylphosphate, 0.1 mM sodium orthovanadate, 10 mM sodium fluoride, phosphatase inhibitor cocktail A and B (Sigma-Aldrich)). The cell lysates were either subjected directly to 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis for immunoblotting analysis or immunoprecipitated for 3 h with the indicated antibodies. Immune complexes were recovered with protein A/G-agarose (Santa Cruz Biotechnology) for 3 h, then washed three times with wash buffer containing 20 mM HEPES (pH 7.4), 50 mM NaCl, 2.5 mM MgCl 2 , 0.1 mM EDTA, and 0.05% Triton X-100. Then the immunoprecipitates or 10% whole cell lysates were resolved on SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes followed by immunobloting analysis using the ECL-Plus Western blotting system (GE Healthcare Biosciences Corp., Pittsburgh, PA, USA) according to the manufacturer's instruction. For DUSP26 immunoblotting cell pellets were lysed in a different lysis buffer (62.5 mM Tris-HCl, 10% SDS, 10% glycerol and 50 mM dithiothreitol). Samples were then sonicated and centrifuged at 13 000 r.p.m. One hundred micrograms of protein were mixed with 0.1% bromophenol blue, boiled and resolved by SDS-polyacrylamide gel electrophoresis.
Fluorescence in situ hybridization Metaphase chromosomes were prepared from six neuroblastoma cell lines (IMR-32, SK-N-SH, SH-SY5Y, SK-N-AS, LAN-1 and JF). Fluorescence in situ hybridization analyses were performed as described previously (Yu et al., 2007) , using BAC RP11-258M15 clone located in the region of interest as probe.
Purification of recombinant GST-DUSP26 proteins
This bacterial expression plasmid (pGEX-DUSP26) was used to purify GST GST-DUSP26-WT or GST-DUSP26-CS from Escherichia coli as described before (Vasudevan et al., 2005) . A modification to the sonication step was made in which 1% Sarcosyl (Sigma-Aldrich) was added to the lysis buffer before sonication, and Triton X-100 (1%), 5 mg/ml DNase, and 5 mg/ ml RNase (Roche) were added after sonication. The recombinant proteins were then eluted with 20 mM glutathione in 50 mM Tris (pH ¼ 8.0) and dialyzed in a buffer containing 20 mM HEPES, 150 mM KCl, 0.2 mM EDTA, 20% glycerol and protease inhibitors. The protein concentrations were then assessed with a Bradford Protein Assay (Bio-Rad). The proteins were visualized by 10% SDS-polyacrylamide gel electrophoresis and Coomassie blue staining of the gel.
RNA interference and overexpression constructs and transduction DUSP26 short hairpin RNA expression was achieved by cloning the following ligated sequences into the pSuper-PURO retrovirus expression vectors per manufacturer's protocol (Oligoengine). The RNA interference target sequences used were as follows: pSuper-Scrambled control (sh-Control), 5 0 -CGTCTTTTCGGACTTAGAGAG-3 0 ; pSuper-DUSP26-1 (sh-DUSP26-1), 5 0 -AAGACAGCCTGTAACCATGCC-3 0 , and pSuper-DUSP26-2 (sh-DUSP26-2), 5 0 -AAGATGTGCCC TGGTAACTGG-3 0 . For retroviral transduction, we used a previously published protocol (Yu et al., 2008) . Stable cell lines were established in IMR-32 cells after 10 days of puromycin (2 mg/ml) selection.
The stable pBabe-vector control, DUSP26-WT and DUSP26-CS cell lines were established in SK-N-SH neuroblastoma cells. A full-length complementary DNA clone containing the DUSP26 gene was obtained from American Type Culture Collection (IMAGE Consortium ID 3535215). DUSP26 ORF was amplified with the following primers: 5 0 -CACCAAGCTTACCATGTGCCCTGGTAACTGG-3 0 and 5 0 -GAGCCAGGGACCTACCCA-3 0 , and cloned into the pcDNA3.1 vector (Invitrogen) (DUSP26-WT). To create a catalytically inactive DUSP26, a serine was substituted for the cysteine at position 152 using a PCR-directed mutagenesis technique as described previously (Maruta et al., 1991) . The DUSP26-CS mutant gene was then cloned into the pcDNA3.1 vector (DUSP26-CS). From this primary construct, DUSP26 was subcloned into p3xFLAG-CMV-10 (FLAG-DUSP26) (Sigma) using HindIII/XbaI. The following primer set, 5-CA CCGGATCCATGTGCCCTGGTAACTG-3 and 5-GAGCC AGGGACCTACCCA-3, was used to subclone DUSP26 into pGEX-KG (Pharmacia) using BamHI/XbaI. This bacterial expression plasmid (pGEX-DUSP26) was used to purify GST GST-DUSP26-WT or GST-DUSP26-CS from E. coli as described before (Vasudevan et al., 2005) .
Luciferase reporter assay
The MDM2-Luc-luciferase reporter plasmid was previously described (Slack et al., 2005) . The Bax-Luc-luciferase reporter plasmid was kindly provided by Dr Lawrence A Donehower (Baylor College of Medicine, Houston, TX, USA). Saos-2 cells were seeded at a concentration of 3 Â 10 5 cells per well and cultured overnight in six-well plates. The p53 expression plasmid, p53-dependent MDM2-firefly-luciferase reporter and the control Renilla luciferase plasmid were co-transfected with empty vector, DUSP26-WT or -CS expression plasmids into the cells. At 24 h after transfection, cells were treated with or without doxorubincin (1 mM) for 24 h and then harvested in lysis buffer (Promega, Madison, WI, USA), luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega). The relative luciferase activity was calculated by dividing the firefly luciferase activity by the Renilla luciferase activity. Data represent three independent experiments performed in duplicate.
CCK-8 cell proliferation assay Cell proliferation was measured by the tetrazolium salt-based proliferation assay (CCK-8 assay; Wako Chemicals, Osaka, Japan) following the manufacturer 0 s instructions and as described previously .
In vitro protein phosphatase assays For in vitro phosphatase assays on phosphopeptides, recombinant DUSP26-WT or -CS mutant proteins prepared from bacterial lysates was diluted in buffer (50 mM Tris-HCl [pH 7.5], 0.1 mM ethyleneglycol tetraacetic acid and 0.02% 2-mercaptoethanol) and incubated with bovine serum albumin (1 mg/ml) and 30 mM MgCl 2 containing 100 mM phosphopeptide for 20 min at 30 1C. Free phosphate was determined using a malachite green/molybdate-based assay following protocols provided by the manufacturer (Promega). Absorbance was measured at 600 nm. The amount of phosphate released was calculated by a phosphate standard curve. The p53-pSer15 (Ac-VEPPL(pS)QETFS-amide), p53-pSer20 (Ac-SQETF(pS) DLWKL-amide), p53-pSer37 (Ac-LSPLP(pS)QAMDD-amide) phosphopeptides were synthesized by New England Peptides (Gardner, MA, USA).
Statistical analyses
A two-tailed Student's t-test was used for statistical analysis of comparative data using Microsoft Excel software (Microsoft DUSP26 is a novel p53 phosphatase X Shang et al
